The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-β signaling

Journal of Clinical Investigation

Volumn 119, Issue 9, 2009, Pages 2678-2690

  Micalizzi, Douglas S ^a   Christensen, Kimberly L ^a   Jedlicka, Paul ^a   Coletta, Ricardo D ^a,d   Barón, Anna E ^a   Harrell, J Chuck ^a   Horwitz, Kathryn B ^a   Billheimer, Dean ^b   Heichman, Karen A ^b,e   Welm, Alana L ^b   Schiemann, William P ^a   Ford, Heide L ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMAD3 PROTEIN; TRANSCRIPTION FACTOR SIX1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; BREAST CARCINOMA; CANCER GROWTH; CANCER SURVIVAL; CELL DIFFERENTIATION; COLON CANCER; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; KIDNEY CANCER; LIVER CANCER; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; RELAPSE; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; EPITHELIUM; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MESODERM; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROGNOSIS; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS;

EID: 70349213381     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37815     Document Type: Article

References (70)

1. Abate-Shen, C. 2002. Deregulated homeobox gene expression in cancer: cause or consequence? Nat. Rev. Cancer. 2:777-785. (Pubitemid 37328912)
2. Xu, P.X., et al. 2003. Six1 is required for the early organogenesis of mammalian kidney. Development. 130:3085-3094.
3. Laclef, C., et al. 2003. Altered myogenesis in Six1-deficient mice. Development. 130:2239-2252.
4. Ford, H.L., Kabingu, E.N., Bump, E.A., Mutter, G.L., and Pardee, A.B. 1998. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 95:12608-12613.
5. Coletta, R.D., et al. 2004. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc. Natl. Acad. Sci. U. S. A. 101:6478-6483.
6. Yu, Y., et al. 2004. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat. Med. 10:175-181. (Pubitemid 38524888)
7. Behbakht, K., et al. 2007. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res. 67:3036-3042. (Pubitemid 46724840)
8. Ng, K.T., et al. 2006. Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma. Br. J. Cancer. 95:1050-1055. (Pubitemid 44606832)
9. Reichenberger, K.J., Coletta, R.D., Schulte, A.P., Varella-Garcia, M., and Ford, H.L. 2005. Gene amplification is a mechanism of Six1 overexpression in breast cancer. Cancer Res. 65:2668-2675. (Pubitemid 40490066)
10. Serra, R., and Crowley, M.R. 2003. TGF-beta in mammary gland development and breast cancer. Breast Dis. 18:61-73. (Pubitemid 39193332)
11. Siegel, P.M., and Massague, J. 2003. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer. 3:807-821. (Pubitemid 37376979)
12. Jakowlew, S.B. 2006. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 25:435-457. (Pubitemid 44922360)
13. Padua, D., et al. 2008. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 133:66-77.
14. Galliher, A.J., Neil, J.R., and Schiemann, W.P. 2006. Role of transforming growth factor-beta in cancer progression. Future Oncol. 2:743-763. (Pubitemid 44941992)
15. Larue, L., and Bellacosa, A. 2005. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 24:7443-7454. (Pubitemid 41637984)
16. Thiery, J.P. 2002. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer. 2:442-454.
17. Steeg, P.S. 2006. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 12:895-904. (Pubitemid 44175140)
18. Lee, J.M., Dedhar, S., Kalluri, R., and Thompson, E.W. 2006. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 172:973-981.
19. Huber, M.A., Kraut, N., and Beug, H. 2005. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17:548-558. (Pubitemid 41267170)
20. Drake, J.M., Strohbehn, G., Bair, T.B., Moreland, J.G., and Henry, M.D. 2009. ZEB1 Enhances Transendothelial Migration and Represses the Epithelial Phenotype of Prostate Cancer Cells. Mol. Biol. Cell. 20:2207-2217.
21. Siegel, P.M., Shu, W., Cardiff, R.D., Muller, W.J., and Massague, J. 2003. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl. Acad. Sci. U. S. A. 100:8430-8435. (Pubitemid 36842562)
22. Grifone, R., et al. 2005. Six1 and Six4 homeoproteins are required for Pax3 and Mrf expression during myogenesis in the mouse embryo. Development. 132:2235-2249. (Pubitemid 40744482)
23. Zavadil, J., and Bottinger, E.P. 2005. TGF-beta and epithelial-to- mesenchymal transitions. Oncogene. 24:5764-5774.
24. Jechlinger, M., et al. 2003. Expression profiling of epithelial plasticity in tumor progression. Oncogene. 22:7155-7169. (Pubitemid 37378548)
25. Huang, Y., et al. 2007. Epithelial to mesenchymal transition in human breast epithelial cells transformed by 17beta-estradiol. Cancer Res. 67:11147-11157. (Pubitemid 350248539)
26. Mani, S.A., et al. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704-715. (Pubitemid 351636299)
27. Brown, K.A., et al. 2004. Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res. 6:R215-R231.
28. Neve, R.M., et al. 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515-527.
29. Kurebayashi, J., et al. 1993. Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and LacZ. Cancer Res. 53:2178-2187. (Pubitemid 23145745)
30. Harrell, J.C., et al. 2006. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res. 66:9308-9315.
31. Janda, E., et al. 2002. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J. Cell Biol. 156:299-313. (Pubitemid 34839911)
32. Waerner, T., et al. 2006. ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. Cancer Cell. 10:227-239. (Pubitemid 44311068)
33. Oft, M., Heider, K.H., and Beug, H. 1998. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol. 8:1243-1252. (Pubitemid 28540052)
34. van de Vijver, M.J., et al. 2002. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:1999-2009. (Pubitemid 35461656)
35. Pawitan, Y., et al. 2005. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 7:R953-R964.
36. Ivshina, A.V., et al. 2006. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 66:10292-10301.
37. Samuel, S., and Naora, H. 2005. Homeobox gene expression in cancer: insights from developmental regulation and deregulation. Eur. J. Cancer. 41:2428-2437. (Pubitemid 41540620)
38. Coletta, R.D., et al. 2008. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Cancer Res. 68:2204-2213.
39. Self, M., et al. 2006. Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney. EMBO J. 25:5214-5228. (Pubitemid 44658538)
40. Bonnin, M.A., et al. 2005. Six1 is not involved in limb tendon development, but is expressed in limb connective tissue under Shh regulation. Mech. Dev. 122:573-585.
41. Rodriguez, S., et al. 2008. Notch2 is required for maintaining sustentacular cell function in the adult mouse main olfactory epithelium. Dev. Biol. 314:40-58.
42. Petropoulos, H., and Skerjanc, I.S. 2002. Beta-catenin is essential and sufficient for skeletal myogenesis in P19 cells. J. Biol. Chem. 277:15393-15399. (Pubitemid 34967801)
43. Vargo-Gogola, T., and Rosen, J.M. 2007. Modelling breast cancer: one size does not fit all. Nat. Rev. Cancer. 7:659-672. (Pubitemid 47327411)
44. Rose, A.A., and Siegel, P.M. 2006. Breast cancer-derived factors facilitate osteolytic bone metastasis. Bull. Cancer. 93:931-943.
45. SAS Institute. 2008. SAS/STAT® 9.2 User's Guide. SAS Institute Inc. Cary, North Carolina, USA. http://support.sas.com/documentation/onlinedoc/stat/ index.html.
46. McClintick, J.N., and Edenberg, H.J. 2006. Effects of filtering by Present call on analysis of microarray experiments. BMC Bioinformatics. 7:49.
47. Li, C., and Wong, W.H. 2001. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. U. S. A. 98:31-36. (Pubitemid 32095858)
48. Ford, H.L., et al. 2000. Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein. J. Biol. Chem. 275:22245-22254.
49. Shtutman, M., Levina, E., Ohouo, P., Baig, M., and Roninson, I.B. 2006. Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. Cancer Res. 66:11370-11380. (Pubitemid 46009968)
50. Korinek, V., et al. 1997. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science. 275:1784-1787. (Pubitemid 27136714)
51. RDC Team. 2008. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria. http://cran.r-project. org/doc/manuals/refman.pdf.
52. Rhodes, D.R., et al. 2004. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 6:1-6.
53. Freije, W.A., et al. 2004. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 64:6503-6510. (Pubitemid 39297907)
54. Shai, R., et al. 2003. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 22:4918-4923. (Pubitemid 36981282)
55. Bachtiary, B., et al. 2006. Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin. Cancer Res. 12:5632-5640. (Pubitemid 44629589)
56. Hummel, M., et al. 2006. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 354:2419-2430. (Pubitemid 43855045)
57. Boer, J.M., et al. 2001. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res. 11:1861-1870. (Pubitemid 33100427)
58. Yang, X.J., et al. 2005. A molecular classification of papillary renal cell carcinoma. Cancer Res. 65:5628-5637. (Pubitemid 40911163)
59. Segal, N.H., et al. 2003. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am. J. Pathol. 163:691-700.
60. Miller, L.D., et al. 2005. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. U. S. A. 102:13550-13555.
61. Huang, E., et al. 2003. Gene expression predictors of breast cancer outcomes. Lancet. 361:1590-1596. (Pubitemid 36578995)
62. LaTulippe, E., et al. 2002. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62:4499-4506. (Pubitemid 34827314)
63. Modlich, O., et al. 2004. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin. Cancer Res. 10:3410-3421. (Pubitemid 38685447)
64. Yu, Y.P., et al. 2004. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22:2790-2799.
65. Bittner, M. 2005. A window on the dynamics of biological switches. Nat. Biotechnol. 23:183-184.
66. Ye, Q.H., et al. 2003. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med. 9:416-423.
67. French, P.J., et al. 2005. Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res. 65:11335-11344. (Pubitemid 41821690)
68. Yamanaka, R., et al. 2006. Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene. 25:5994-6002. (Pubitemid 44477293)
69. Cario, G., et al. 2005. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood. 105:821-826. (Pubitemid 40070770)
70. Hess, K.R., et al. 2006. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24:4236-4244. (Pubitemid 46630780)